Cytochrome P450 2C9, Novartis
Also known as: CYP2C9, 2C9
Use
This germline pharmacogenetic test evaluates variants in the CYP2C9 gene, which encodes a drug-metabolizing enzyme. Results can inform dosing and minimize toxicity, particularly for medications metabolized by CYP2C9 such as warfarin.
Special Instructions
Physician attestation of informed consent is required when ordering from facilities in AK, DE, FL, GA, IA, MN, NV, NJ, NY, OR, SD, VT, or if performed in MA.
Limitations
The test analyzes only CYP2C9 gene variants; it does not assess other pharmacogenomic markers. Genetic variation is one of several factors affecting drug metabolism; clinical context and judgment remain critical.
Methodology
PCR-based (PCR)
Biomarkers
Result Turnaround Time
7 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
5 mL
Minimum Volume
3 mL
Container
EDTA (lavender or royal blue-top), ACD solution B (yellow‑top), sodium or lithium heparin (green‑top) tube
Collection Instructions
Normal phlebotomy procedure
Storage Instructions
Store and ship ambient immediately. Do not freeze.
Causes for Rejection
Shipping refrigerated or frozen unacceptable
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 8 days |
| Refrigerated | 8 days |
| Frozen | Unacceptable |